Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience

Background. Treatment results in patients with relapsed and refractory acute myeloid leukemia (AML) remain unsatis‑factory. Treatment options for these patients are limited.Aim. To retrospectively analyze the efficacy and safety of combined therapy with hypomethylating agents and venetoclax (VenHMA)...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Онкогематология
المؤلفون الرئيسيون:	M. A. Granatkin, E. A. Nikitin, M. I. Kislova, E. S. Mikhailov, V. A. Doronin, S. V. Minenko, M. M. Okuneva, A. V. Antonova, N. V. Degtyareva, M. E. Pochtar, S. A. Lugovskaya, Yu. N. Kobzev, V. V. Ptushkin, E. V. Rimashevskaya
التنسيق:	مقال
اللغة:	الروسية
منشور في:	ABV-press 2023-03-01
الموضوعات:	acute myeloid leukemia refractory relapse venetoclax hypomethylating agents
الوصول للمادة أونلاين:	https://oncohematology.abvpress.ru/ongm/article/view/793